Abstracts tagged "glucocorticoids"

Abstract Number: 0995 • ACR Convergence 2022
Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
Patricia Katz¹, Sofia Pedro², Jiyoon Choi³ and Kaleb Michaud⁴, ¹UCSF, San Rafael, CA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for systemic lupus erythematosus (SLE). While GCs do provide benefit, there are potential side effects…
Abstract Number: 1996 • ACR Convergence 2022
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Lotte van Ouwerkerk¹, Patrick Verschueren², Pascal de Jong³, Paul Emery⁴, Josef Smolen⁵, Robert Landewé⁶, Willem Lems⁷, Maarten Boers⁸, Tom Huizinga¹, CF Allaart¹ and Sytske Anne Bergstra⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Leuven, Leuven, Belgium, ³ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Medical University of Vienna, Vienna, Austria, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹LUMC, Leiden, Netherlands
Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
Abstract Number: 0178 • ACR Convergence 2022
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
Margherita Giannini¹, Daniela Rovito², Léa Debrut³, Céline Keime⁴, Beatrice Lannes⁵, Anne-Laure Charles³, Delphine Duteil², Bernard Geny⁶, Daniel Metzger², Gilles Laverny² and Alain Meyer¹, ¹Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; Centre de Référence des Maladies Autoimmunes Rares, CHU, Strasbourg ; UR3072, Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ²University of Strasbourg, CNRS UMR7104, INSERM U1258, IGBMC, F-67400, Illkirch, France, ³UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ⁴University of Strasbourg, CNRS UMR 7104, INSERM UMR-S 1258, IGBMC, F-67400, Illkirch, France, ⁵Département de pathologie, Centre de référence des maladies neuromusculaires, CHU Strasbourg, University of Strasbourg, Strasbourg, France, ⁶Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France
Background/Purpose: Glucocorticoids (GC) are the first line treatment for myositis patients. They improve muscle strength, yet muscle recovery is generally partial and long lasting treatment…
Abstract Number: 0997 • ACR Convergence 2022
Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Aishwarya Gopal¹, Chengappa Kavadichanda², Devender Bairwa³, Molly Mary Thabah⁴ and Vir Singh Negi⁵, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁴JIPMER, Puducherry, Puducherry, India, ⁵AIIMS Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Attempts to stop glucocorticoids among Systemic Lupus Erythematosus(SLE) patients in long term remission have been successful. Continuing other immunosuppressive (IS) agents indefinitely is currently…
Abstract Number: 2000 • ACR Convergence 2022
Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis Patients: Follow up of the Pragmatic, Multicentre, Placebo-controlled GLORIA Trial
Abdullah Almayali¹, Maarten Boers², Linda Hartman³, Daniela OPRIS-BELINSKI⁴, Reinhard Bos⁵, Marc Kok⁶, Jose Pereira da Silva⁷, Eduard N Griep⁸, Ruth Klaasen⁹, CF Allaart¹⁰, Paul Baudoin¹¹, Hennie Raterman¹², Zoltan Szekanecz¹³, Frank Buttgereit¹⁴, Pavol MASARYK¹⁵, Willem Lems¹⁶, Maurizio Cutolo¹⁷ and Marieke ter Wee³, ¹Amsterdam University Medical Centers, Vrije Universiteit, Purmerend, Noord-Holland, Netherlands, ²Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ³Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁴Carol Davila University, Bucharest, Romania, ⁵Medical Centre Leeuwarden, Department of Rheumatology, Leeuwarden, Netherlands, ⁶Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁷University of Coimbra, Rheumatology, Columbia, Portugal, ⁸Department of Rheumatology, Antonius Hospital, Leeuwarden, Netherlands, ⁹Department of Rheumatology, Meander Medical Center, Amersfoort, Netherlands, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Reumazorg Flevoland, Almere, Netherlands, ¹²Department of Rheumatology, Northwest Clinics, Alkmaar, Netherlands, ¹³Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ¹⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ¹⁵National Institute for the Rheumatic Diseases, Piešťany, Slovakia, ¹⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: Guidelines suggest glucocorticoids (GC) should be used as bridge therapy in rheumatoid arthritis (RA), but many patients are on chronic treatment, and the effects…
Abstract Number: 0458 • ACR Convergence 2022
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
Despina Michailidou¹, Tianyu Zhang², Andreas Diamantopoulos³, Pavlos Stamatis⁴ and Bernard Ng⁵, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Akershus University Hospital, Lørenskog, Norway, ⁴Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ⁵Rheumatology Section, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is an independent risk factor for thromboembolic events. The purpose of our study was to identify prognostic factors for thromboembolic…
Abstract Number: 1041 • ACR Convergence 2022
Tofacitinib in Refractory Uveitis – an Observational Study
Nikhil Gupta¹ and Deepankur Mahajan², ¹Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, ²Mahajan Eye Centre, New Delhi, India
Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 0459 • ACR Convergence 2022
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
Hampus Henningson¹, Björn Hammar², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Ophthalmology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the age-group 50 years and older. Cranial involvement is common and can lead to…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 0460 • ACR Convergence 2022
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Naomi Patel¹, Xiaoqing Fu², yuqing zhang³ and John Stone⁴, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 2072 • ACR Convergence 2022
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Ilana Usiskin and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…
Abstract Number: 0461 • ACR Convergence 2022
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
Naomi Patel¹, Veronica Tozzo², John Higgins² and John Stone³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…

« Previous Page
1
…
7
8
9
10
11
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].